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The glioneuronal tumor with neuropil-like islands (GTNI)
is an uncommon histopathological entity composed of
diffuse astrocytic or oligoastrocytic elements interspersed
with sharply delimited, micronodular loci of neuronal dif-
ferentiation. Despite its initial description over 10 years
ago [10], the lineage classiﬁcation of GTNI remains
speculative. The clinical features of GTNI, its inﬁltrative
growth characteristics, typically dominating astroglial
components, and frequent p53 expression, are all consistent
with a fundamental linkage to the diffuse astrocytic tumor
group. Supporting this notion are reports documenting, by
comparative genomic hybridization, an astrocytoma-like
proﬁle of 7q21.1-qter gain and 9p21-pter loss in one case
[8] and the absence of oligodendroglioma-associated 1p/
19q deletions in a series assessed by polymerase chain
reaction-based loss of heterozygosity analysis [3].
Point mutations in the isocitrate dehydrogenase
enzymes, IDH1 and IDH2, are found in the majority of
WHO grade II and III diffuse gliomas—both astrocytic and
oligodendroglial—as well as secondary glioblastomas
(GBM), but they are almost entirely absent from primary
GBM [7, 9, 11]. As such, they appear to represent a
deﬁning early genomic lesion in the pathogenesis of diffuse
glioma variants exhibiting step-wise malignant evolution.
Glioma-associated IDH mutations invariably involve active
site arginine residues—R132 and R172 for IDH1 and
IDH2, respectively—and, while their precise pathogenic
mechanism remains unclear, they appear to promote the
generation of the cancer-predisposing toxic metabolite,
R(-)-2-hydroxyglutarate [6].
We assembled 12 cases of GTNI (Table 1) seen at the
Memorial Hospital Department of Pathology, along with
pertinent clinical information from the patients’ medical
records. To evaluate whether IDH1 and IDH2 mutations
were present in our sample set, we performed custom
genotyping assays on the Sequenom platform [1, 2] and/or
employed validated immunohistochemical staining (IHC)
for the most common IDH mutation, IDH1 R132H [5]. We
found that every tumor in our sample set (12/12) exhibited
evidence of the IDH1 R132H mutation by either one or
both of our assay methods (Fig. 1a–d), and concordant
results were achieved for all cases screened by both
Sequenom
 and IHC (Table 1). Both glial and neuronal
components exhibited immuno-expression of mutant IDH1
in all examined cases (Fig. 1d).
The primary signiﬁcance of our ﬁndings lies in
strengthening the pathogenic link between GTNIs and the
diffuse glioma tumor group. Studies to date indicate that
within primary brain tumors, IDH mutations are largely
restricted to diffuse gliomas evolving via step-wise
malignant evolution (i.e., diffuse astrocytomas, oligoden-
drogliomas, and oligoastrocytomas). Combined with the
frequent p53 immunoreactivity and general absence of
1p/19q chromosomal co-deletions previously documented
in this setting, a high incidence of IDH1 mutations would
fundamentally ally GTNIs with the diffuse astrocytoma
and 1p/19q-intact oligoastrocytoma group. Indeed, the
100% incidence of IDH mutation in our sample set is even
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DOI 10.1007/s00401-011-0855-6higher than that documented in diffuse astrocytoma so
far (*80%) [7, 11]. As an aside, recent work has also
identiﬁed IDH mutation as a prevalent feature of oligo-
dendrogliomas with neurocytic differentiation [4], further
emphasizing that focally prominent neuronal morphology
falls well within the histopathological spectrum of diffuse
gliomas in general. The invariable presence of the speciﬁc
IDH1 R132H mutation in our GTNIs may represent an
artifact of small sample number, but, nevertheless, it is
striking. Whether other IDH1 or IDH2 mutational variants
exist in GTNI and whether a genotypic restriction to IDH1
R132H alone would have any functional signiﬁcance
remain unclear.
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Table 1 Cases included in GTNI study cohort listed with patient age at ﬁrst diagnosis, sex, histopathological grade (Grade), Sequenom

genotyping result (Sequenom) and IHC for IDH1 R132H (R132H IHC)
Case Age Sex Grade Sequenom R132H IHC
1 70 M LG R132H NA
2
a 40 M HG: MVP/NEC R132H NA
3
a 57 M LG R132H NA
4
a 56 M HG R132H NA
5
a 40 M LG R132H ?
6
a 38 M LG R132H ?
7
a 47 M LG R132H ?
8 43 F LG R132H NA
9 40 M HG NA ?
10
a 41 M LG R132H ?
11 53 F HG NA ?
12 29 F HG R132H ?
M male, F female, LG low-grade, HG high-grade, MVP microvascular proliferation, NEC necrosis, R132H IDH1 R132H mutation
a Cases included in a previous study of 1p/19q co-deletion in GTNI [3]
Fig. 1 GTNI is characterized
by IDH1 R132H mutations. a A
mutation-positive Sequenom

spectrum from a representative
GTNI sample displays an
additional extension product of
different mass, due to the G to A
point mutation.
Photomicrographs of a
representative case of GTNI
stained with H&E (b) and
immunostained for
synaptophysin (c) and IDH1
R132H (d). All micrographs
were taken at 9400
magniﬁcation and reﬂect the
same high-power ﬁeld. Note
mutant IDH1 labeling within
both the neuropil-like island at
right as well as the
synaptophysin-negative glial
component
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